Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Characterization of mutational signatures, gene expression patterns and immune populations in metastatic nodal and bladder tumor tissue to predict response to primary chemotherapy in node positive bladder cancer.

Funder: Bladder Cancer Advocacy Network

Funding period
USD 2 K
Funding amount
Abstract
Research ProposalBackgroundPatients with metastatic bladder cancer limited to the pelvic lymph nodes have improved rates of response to chemotherapy and better outcomes compared to those with widely metastatic disease. Research identifying biomarkers or subtypes to predict sensitivity to chemotherapy exclude node positive patients or only make up only a small subset. Additionally, these studies use bladder tumor tissue for analysis and have not analyzed lymph node positive tissue. This assumes that bladder tumors are surrogate predictors for response of micrometastatic or metastatic disease to the nodes, which is unknown. This is an important distinction as there may be unique signatures within the lymph node positive tissue not present in bladder tumor that can better predict response to chemotherapy. Interestingly, molecular subtype classification of bladder tumor tissue can be distinct from synchronous lymph node tissue. HypothesisDistinct mutational signatures, gene expression patterns and immune landscapes in node positive tissue more accurately predicts nodal response to chemotherapy and outcomes compared to matched bladder tumors. MethodsData was retrospectively collected from patients with cTanyN1-3M0 bladder cancer who underwent radical cystectomy at the University of Texas MD Anderson Cancer Center. A subset of these patients underwent lymph node biopsy prior to chemotherapy to determine true nodal status. Nodal and bladder response to chemotherapy was based on final pathology at cystectomy. Recurrence free and overall survival were determined. Next Generation Sequencing and mass spectrometry based methods (cytometry by time of flight, i.e. CyTOF) will be used to identify unique markers in bladder tumor and matched node tissue from biopsy prior to chemotherapy to identify novel immune signatures and molecular markers of predictors of response to chemotherapy.
Similar projects All >
Sorted by: Start Date
Project list item
Developing a SMART scaffold for bladder augmentation

National Institute of Biomedical Imaging and Bioengineering to GUILLERMO ANTONIO AMEER, JOHN ROGERS, ARUN SHARMA

USD 709,004
2019 - 2023
Project list item
Investigating underlying molecular mechanisms of epigenetic therapies in muscle-invasive bladder cancer

Bladder Cancer Advocacy Network to Swathi Ramakrishnan

USD 1,700
2019 - 2019
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Targeting FGF in Bladder cancer after Neoadjuvant Immunotherapy and Surgery

American Association For Cancer Research to Joshua James Meeks

USD 25,000
2019 - 2020

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • HRCS RAC

    4.2 Evaluation of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science